There’s growing interest in cannabinoids for their therapeutic potential in a range of conditions, but one challenge therapeutic developers face is a reliable and consistent supply. Teewinot Life Sciences is using synthetic biology to produce a range of cannabinoids. We spoke to Michael Luther, president and CEO of Teewinot Life Sciences, about the companies process for producing cannabinoids, its business model, and the therapeutic and consumer areas it plans to pursue.